NOMURA HOLDINGS INC-SPON ADR (NMR) Stock Fundamental Analysis
USA - NYSE:NMR - US65535H2085 - ADR
7.55 USD
+0.04 (+0.53%)
7.55 USD
0 (0%)
Overall NMR gets a fundamental rating of 3 out of 10. We evaluated NMR against 237 industry peers in the Capital Markets industry. NMR may be in some trouble as it scores bad on both profitability and health. NMR is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
NMR had positive earnings in the past year.
NMR had a negative operating cash flow in the past year.
In the past 5 years NMR has always been profitable.
The reported operating cash flow has been mixed in the past 5 years: NMR reported negative operating cash flow in multiple years.
1.2 Ratios
NMR has a worse Return On Assets (0.60%) than 69.62% of its industry peers.
Looking at the Return On Equity, with a value of 9.82%, NMR is in line with its industry, outperforming 56.54% of the companies in the same industry.
NMR has a worse Return On Invested Capital (0.63%) than 71.31% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for NMR is significantly below the industry average of 7.61%.
The last Return On Invested Capital (0.63%) for NMR is above the 3 year average (0.42%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.6% | ||
| ROE | 9.82% | ||
| ROIC | 0.63% |
ROA(3y)0.36%
ROA(5y)0.36%
ROE(3y)5.9%
ROE(5y)5.66%
ROIC(3y)0.42%
ROIC(5y)0.41%
1.3 Margins
NMR's Profit Margin of 7.19% is on the low side compared to the rest of the industry. NMR is outperformed by 64.13% of its industry peers.
In the last couple of years the Profit Margin of NMR has declined.
NMR's Operating Margin of 9.96% is on the low side compared to the rest of the industry. NMR is outperformed by 68.78% of its industry peers.
In the last couple of years the Operating Margin of NMR has declined.
Looking at the Gross Margin, with a value of 39.95%, NMR is doing worse than 64.13% of the companies in the same industry.
In the last couple of years the Gross Margin of NMR has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.96% | ||
| PM (TTM) | 7.19% | ||
| GM | 39.95% |
OM growth 3Y-11.17%
OM growth 5Y-4.76%
PM growth 3Y-7.1%
PM growth 5Y-8.33%
GM growth 3Y-22.42%
GM growth 5Y-9.54%
2. Health
2.1 Basic Checks
NMR has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, NMR has less shares outstanding
The debt/assets ratio for NMR has been reduced compared to a year ago.
2.2 Solvency
NMR has an Altman-Z score of -0.27. This is a bad value and indicates that NMR is not financially healthy and even has some risk of bankruptcy.
NMR's Altman-Z score of -0.27 is on the low side compared to the rest of the industry. NMR is outperformed by 75.95% of its industry peers.
A Debt/Equity ratio of 10.44 is on the high side and indicates that NMR has dependencies on debt financing.
NMR has a Debt to Equity ratio of 10.44. This is amonst the worse of the industry: NMR underperforms 89.03% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 10.44 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.27 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
NMR has a Current Ratio of 0.22. This is a bad value and indicates that NMR is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.22, NMR is doing worse than 87.76% of the companies in the same industry.
NMR has a Quick Ratio of 0.22. This is a bad value and indicates that NMR is not financially healthy enough and could expect problems in meeting its short term obligations.
NMR's Quick ratio of 0.22 is on the low side compared to the rest of the industry. NMR is outperformed by 87.34% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.22 | ||
| Quick Ratio | 0.22 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 79.28% over the past year.
Measured over the past years, NMR shows a quite strong growth in Earnings Per Share. The EPS has been growing by 10.96% on average per year.
NMR shows a small growth in Revenue. In the last year, the Revenue has grown by 4.32%.
Measured over the past years, NMR shows a quite strong growth in Revenue. The Revenue has been growing by 19.39% on average per year.
EPS 1Y (TTM)79.28%
EPS 3Y34.65%
EPS 5Y10.96%
EPS Q2Q%62.38%
Revenue 1Y (TTM)4.32%
Revenue growth 3Y43.77%
Revenue growth 5Y19.39%
Sales Q2Q%-4.36%
3.2 Future
NMR is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.23% yearly.
Based on estimates for the next years, NMR will show a decrease in Revenue. The Revenue will decrease by -6.34% on average per year.
EPS Next Y-2.18%
EPS Next 2Y-0.93%
EPS Next 3Y0.23%
EPS Next 5YN/A
Revenue Next Year-21.32%
Revenue Next 2Y-10.98%
Revenue Next 3Y-6.34%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 8.39, the valuation of NMR can be described as reasonable.
NMR's Price/Earnings ratio is rather cheap when compared to the industry. NMR is cheaper than 81.86% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.27. NMR is valued rather cheaply when compared to this.
Based on the Price/Forward Earnings ratio of 9.53, the valuation of NMR can be described as reasonable.
Based on the Price/Forward Earnings ratio, NMR is valued a bit cheaper than the industry average as 77.64% of the companies are valued more expensively.
NMR's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.77.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.39 | ||
| Fwd PE | 9.53 |
4.2 Price Multiples
NMR's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. NMR is cheaper than 70.04% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 22.88 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)0.77
EPS Next 2Y-0.93%
EPS Next 3Y0.23%
5. Dividend
5.1 Amount
NMR has a Yearly Dividend Yield of 3.94%.
NMR's Dividend Yield is comparable with the industry average which is at 7.96.
NMR's Dividend Yield is rather good when compared to the S&P500 average which is at 2.38.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.94% |
5.2 History
On average, the dividend of NMR grows each year by 15.59%, which is quite nice.
NMR has been paying a dividend for at least 10 years, so it has a reliable track record.
The dividend of NMR decreased in the last 3 years.
Dividend Growth(5Y)15.59%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
33.03% of the earnings are spent on dividend by NMR. This is a low number and sustainable payout ratio.
The dividend of NMR is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP33.03%
EPS Next 2Y-0.93%
EPS Next 3Y0.23%
7.55
+0.04 (+0.53%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)
Earnings (Next)
Inst Owners38.49%
Inst Owner Change4.93%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap22.15B
Analysts73.33
Price Target7.73 (2.38%)
Short Float %0.06%
Short Ratio2.96
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.94% |
Yearly Dividend0.27
Dividend Growth(5Y)15.59%
DP33.03%
Div Incr Years2
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)23.99%
Min EPS beat(2)-10.21%
Max EPS beat(2)58.19%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)9.65%
PT rev (3m)7.94%
EPS NQ rev (1m)-0.18%
EPS NQ rev (3m)177.61%
EPS NY rev (1m)2.05%
EPS NY rev (3m)3.62%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)-18.31%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.39 | ||
| Fwd PE | 9.53 | ||
| P/S | 0.69 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.94 | ||
| P/tB | 0.96 | ||
| EV/EBITDA | 22.88 |
EPS(TTM)0.9
EY11.92%
EPS(NY)0.79
Fwd EY10.49%
FCF(TTM)-3.57
FCFYN/A
OCF(TTM)-1.56
OCFYN/A
SpS10.92
BVpS8
TBVpS7.83
PEG (NY)N/A
PEG (5Y)0.77
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.6% | ||
| ROE | 9.82% | ||
| ROCE | 1.65% | ||
| ROIC | 0.63% | ||
| ROICexc | 0.69% | ||
| ROICexgc | 0.7% | ||
| OM | 9.96% | ||
| PM (TTM) | 7.19% | ||
| GM | 39.95% | ||
| FCFM | N/A |
ROA(3y)0.36%
ROA(5y)0.36%
ROE(3y)5.9%
ROE(5y)5.66%
ROIC(3y)0.42%
ROIC(5y)0.41%
ROICexc(3y)0.46%
ROICexc(5y)0.45%
ROICexgc(3y)0.46%
ROICexgc(5y)0.46%
ROCE(3y)1.09%
ROCE(5y)1.09%
ROICexcg growth 3Y16.87%
ROICexcg growth 5Y8.04%
ROICexc growth 3Y16.9%
ROICexc growth 5Y8.08%
OM growth 3Y-11.17%
OM growth 5Y-4.76%
PM growth 3Y-7.1%
PM growth 5Y-8.33%
GM growth 3Y-22.42%
GM growth 5Y-9.54%
F-Score6
Asset Turnover0.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 10.44 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 67.92 | ||
| Cap/Depr | 1410.99% | ||
| Cap/Sales | 18.37% | ||
| Interest Coverage | 0.16 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.22 | ||
| Quick Ratio | 0.22 | ||
| Altman-Z | -0.27 |
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)988.49%
Cap/Depr(5y)668.06%
Cap/Sales(3y)14.69%
Cap/Sales(5y)11.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)79.28%
EPS 3Y34.65%
EPS 5Y10.96%
EPS Q2Q%62.38%
EPS Next Y-2.18%
EPS Next 2Y-0.93%
EPS Next 3Y0.23%
EPS Next 5YN/A
Revenue 1Y (TTM)4.32%
Revenue growth 3Y43.77%
Revenue growth 5Y19.39%
Sales Q2Q%-4.36%
Revenue Next Year-21.32%
Revenue Next 2Y-10.98%
Revenue Next 3Y-6.34%
Revenue Next 5YN/A
EBIT growth 1Y72.34%
EBIT growth 3Y27.7%
EBIT growth 5Y13.71%
EBIT Next Year20361.5%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-122.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-883.38%
OCF growth 3YN/A
OCF growth 5YN/A